BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31725476)

  • 1. Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review.
    Guerdjikova AI; Blom TJ; Mori N; Matthews A; Cummings T; Casuto LL; McElroy SL
    Clin Neuropharmacol; 2019; 42(6):214-216. PubMed ID: 31725476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
    Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
    Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
    McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
    Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
    Kornstein SG; Bliss C; Kando J; Madhoo M
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
    Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
    JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
    McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
    Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
    McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
    Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisdexamfetamine: A Review in Binge Eating Disorder.
    Heo YA; Duggan ST
    CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder.
    Schneider E; Higgs S; Dourish CT
    Eur Neuropsychopharmacol; 2021 Dec; 53():49-78. PubMed ID: 34461386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe.
    Siffel C; Page M; Maxwell T; Thun B; Kolb N; Rosenlund M; von Bredow D; Keja J
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):439-447. PubMed ID: 32315539
    [No Abstract]   [Full Text] [Related]  

  • 12. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
    Ward K; Citrome L
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In brief: lisdexamfetamine (Vyvanse) for binge eating disorder.
    Med Lett Drugs Ther; 2015 Mar; 57(1464):42. PubMed ID: 25758546
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.
    Schneider E; Martin E; Rotshtein P; Qureshi KL; Chamberlain SR; Spetter MS; Dourish CT; Higgs S
    Transl Psychiatry; 2022 Jan; 12(1):9. PubMed ID: 35013131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA.
    Ágh T; Pawaskar M; Nagy B; Lachaine J; Vokó Z
    Clin Drug Investig; 2016 Apr; 36(4):305-12. PubMed ID: 26914658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
    Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
    J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice.
    Amodeo G; Cuomo A; Bolognesi S; Goracci A; Trusso MA; Piccinni A; Neal SM; Baldini I; Federico E; Taddeucci C; Fagiolini A
    Expert Opin Pharmacother; 2019 Apr; 20(6):679-690. PubMed ID: 30696303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.